CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 60 enrolled
Drug / intervention
Naloxone +4 moredrug
Likely dose
Naloxone 0.15 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03419858
NCT03419858Early Ph 1Completed

The Role of Endogenous Opioidergic Systems in Breathing Based Analgesia

University of California, San Diego·interventional·Posted Feb 5, 2018·Updated Jun 11, 2019

In Brief

A Early Phase 1 clinical trial evaluating Mindfulness Meditation, Placebo Meditation, and 3 other interventions for Pain. Completed, enrolled 60 participants across 1 site.

Detailed Summary

The purpose of this psychophysical and pharmacologic study is to determine if slow-breathing induced pain relief is mediated by endogenous opioids in response to intravenous (IV) administration of the opioid antagonist naloxone during noxious heat stimulation. We were also interested in disentangling the endogenous analgesic mechanisms supporting mindfulness-based analgesia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain
CountriesUnited States
Collaborators--

Timeline

Early Ph 1CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 5, 2018
Enrollment StartMar 13, 2017
Primary CompletionJun 27, 2017
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 8.4 years ago

Interventions

Mindfulness Meditationbehavioral

A well-validated brief mindfulness-based mental training regimen \[four sessions; 20 min/session\] was used to teach patients to independently practice mindfulness meditation.

Placebo Meditationbehavioral

A well-validated brief meditation-based mental training regimen \[four sessions; 20 min/session\] was used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.

Slow-Breathingbehavioral

Study volunteers practiced lowering their breathing rate, across four, 20 minute training sessions, in response to a fluctuating light with the guidance of a trained facilitator.

Naloxonedrug

A 0.15 mg/kg bolus dose of naloxone (Naloxone Hydrichloride, Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California) in 25ml normal saline was administered over 10 minutes. We also administered a supplementary IV infusion dose of 0.1mg/kg/hour naloxone immediately after bolus infusion ceased till the end of the experiment.

Salineother

A 0.15 mg/kg bolus dose of saline in 25ml normal saline was administered over 10 minutes. We also administered a supplementary IV infusion dose of 0.1mg/kg/hour saline immediately after bolus infusion ceased till the end of the experiment.